Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer.

Gwak HS, Joo J, Kim S, Yoo H, Shin SH, Han JY, Kim HT, Lee JS, Lee SH.

J Thorac Oncol. 2013 May;8(5):599-605. doi: 10.1097/JTO.0b013e318287c943.

2.

Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.

Lee E, Keam B, Kim DW, Kim TM, Lee SH, Chung DH, Heo DS.

J Thorac Oncol. 2013 Aug;8(8):1069-74. doi: 10.1097/JTO.0b013e318294c8e8.

3.

Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era.

Park JH, Kim YJ, Lee JO, Lee KW, Kim JH, Bang SM, Chung JH, Kim JS, Lee JS.

Lung Cancer. 2012 Jun;76(3):387-92. doi: 10.1016/j.lungcan.2011.11.022. Epub 2011 Dec 18.

PMID:
22186628
4.

Intraventricular chemotherapy for leptomeningeal carcinomatosis from lung cancer: a feasible and beneficial treatment option?

Christoph DC, Reckamp KL.

J Thorac Oncol. 2013 May;8(5):523-4. doi: 10.1097/JTO.0b013e31828b518a. No abstract available.

5.

Ventriculolumbar perfusion chemotherapy with methotrexate for treating leptomeningeal carcinomatosis: a Phase II Study.

Gwak HS, Joo J, Shin SH, Yoo H, Han JY, Kim HT, Yun T, Ro J, Lee JS, Lee SH.

Oncologist. 2014 Oct;19(10):1044-5. doi: 10.1634/theoncologist.2014-0199. Epub 2014 Sep 10.

6.

Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era.

Riess JW, Nagpal S, Iv M, Zeineh M, Gubens MA, Ramchandran K, Neal JW, Wakelee HA.

Clin Lung Cancer. 2014 May;15(3):202-6. doi: 10.1016/j.cllc.2013.12.009. Epub 2014 Jan 1.

PMID:
24524822
7.

Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study.

Scott BJ, van Vugt VA, Rush T, Brown T, Chen CC, Carter BS, Schwab R, Fanta P, Helsten T, Bazhenova L, Parker B, Pingle S, Saria MG, Brown BD, Piccioni DE, Kesari S.

J Neurooncol. 2014 Sep;119(2):361-8. doi: 10.1007/s11060-014-1486-2. Epub 2014 Jun 19.

PMID:
24942463
8.

Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations.

Gong L, Xiong M, Huang Z, Miao L, Fan Y.

Lung Cancer. 2015 Sep;89(3):268-73. doi: 10.1016/j.lungcan.2015.06.001. Epub 2015 Jun 24.

PMID:
26141219
9.

ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis.

Ahn HK, Han B, Lee SJ, Lim T, Sun JM, Ahn JS, Ahn MJ, Park K.

Lung Cancer. 2012 May;76(2):253-4. doi: 10.1016/j.lungcan.2012.02.003. Epub 2012 Mar 3.

PMID:
22385925
10.

Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors.

Lee SJ, Lee JI, Nam DH, Ahn YC, Han JH, Sun JM, Ahn JS, Park K, Ahn MJ.

J Thorac Oncol. 2013 Feb;8(2):185-91. doi: 10.1097/JTO.0b013e3182773f21.

11.

Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy.

Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM.

J Thorac Oncol. 2012 Feb;7(2):382-5. doi: 10.1097/JTO.0b013e3182398e4f.

12.

Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy.

Chamberlain MC, Kormanik P.

Arch Neurol. 1998 Apr;55(4):506-12.

PMID:
9561978
13.

Chemoport with a non-collapsible chamber as a replacement for an Ommaya reservoir in the treatment of leptomeningeal carcinomatosis.

Gwak HS, Lee CH, Yang HS, Joo J, Shin SH, Yoo H, Lee JS, Lee SH.

Acta Neurochir (Wien). 2011 Oct;153(10):1971-8; discussion 1978. doi: 10.1007/s00701-011-1086-2. Epub 2011 Jul 28.

PMID:
21796363
14.

Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.

Lilenbaum R, Axelrod R, Thomas S, Dowlati A, Seigel L, Albert D, Witt K, Botkin D.

J Clin Oncol. 2008 Feb 20;26(6):863-9. doi: 10.1200/JCO.2007.13.2720.

PMID:
18281658
15.

Whole brain radiotherapy in management of non-small-cell lung carcinoma associated leptomeningeal carcinomatosis: evaluation of prognostic factors.

Ozdemir Y, Yildirim BA, Topkan E.

J Neurooncol. 2016 Sep;129(2):329-35. doi: 10.1007/s11060-016-2179-9. Epub 2016 Jun 15.

PMID:
27306442
16.

Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib.

Ariyasu R, Horiike A, Koyama J, Saiki M, Sonoda T, Kawashima Y, Takano N, Oguri T, Nishikawa S, Kitazono S, Yanagitani N, Ohyanagi F, Nishio M.

Anticancer Drugs. 2017 Jun;28(5):565-567. doi: 10.1097/CAD.0000000000000489.

PMID:
28225456
17.

Less toxic chemotherapy improves uptake of all lines of chemotherapy in advanced non-small-cell lung cancer: a 10-year retrospective population-based review.

Ho C, Ramsden K, Zhai Y, Murray N, Sun S, Melosky B, Laskin J.

J Thorac Oncol. 2014 Aug;9(8):1180-6. doi: 10.1097/JTO.0000000000000225.

18.

[Clinical features and prognostic factors in patients with leptomeningeal metastases].

Li N, Yang BY, Li JL, Zhu JQ, Zou BH, Wang YF, Yu L, Yao XY.

Zhonghua Zhong Liu Za Zhi. 2013 Nov;35(11):867-70. Chinese.

PMID:
24447488
19.

High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases--one with a remarkable thoracic response as well.

Kuiper JL, Smit EF.

Lung Cancer. 2013 Apr;80(1):102-5. doi: 10.1016/j.lungcan.2012.12.024. Epub 2013 Feb 1.

PMID:
23375403
20.

[Analysis of Clinicopathological Feature and Prognosis for ‚Ä©Leptomeningeal Metastasis in Non-small Cell Lung Cancer].

Zhu M, Ren Y, Liu Y, Ban C, Gu H, Wang Z, Zhang Y.

Zhongguo Fei Ai Za Zhi. 2016 Aug 20;19(8):533-8. doi: 10.3779/j.issn.1009-3419.2016.08.09. Chinese.

Supplemental Content

Support Center